The United States of America; as Represented by the Secretary; Department of Health and Human Services
发明人:
Law, Amanda J.,Weinberger, Daniel R.
申请号：
AU2009322187
公开号：
AU2009322187B2
申请日:
2009.12.04
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.
